SCROLL DOWN TO SEE THE LATEST NEWS
PRA HEALTH SCIENCES TO REPORT FIRST QUARTER 2016 EARNINGS
PRA Health Sciences to Report Fourth Quarter 2015 Earnings
WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China
PRA Health Sciences Expands Operations in Singapore
PRA Health Sciences, inc. Reports third quarter 2015 results and provides updated 2015 guidance
PRA Health Sciences Opens New Bioanalytical Laboratory in the Netherlands
PRA Health Sciences Announces Appointment of New Director
PRA Health Sciences Collaborates with AMR to Accelerate Vaccine Development
PRA Health Sciences, Inc. Reports Second Quarter 2015 Results and Provides Updated Guidance for 2015
- $336.5 million of service revenue in the second quarter; 12% constant currency growth compared to the second quarter of 2014
- $61.3 million of Adjusted EBITDA in the second quarter; 35% growth compared to the second quarter of 2014
- Second quarter Adjusted Net Income per share increased 37% to $0.47 per share and Adjusted Net Income increased 112% to $29.7 million compared to the second quarter of 2014
- Second quarter GAAP Net Income was $12.4 million or ... Read More
PRA Health Sciences Looks to Expand Workforce in Pennsylvania
PRA Health Sciences Launches New Initiative to Bolster Workforce
PRA Health Sciences Announces Time Change for Second Quarter 2015 Financial Results Conference Call
PRA Health Sciences to Report Second Quarter 2015 Results
PRA Continues the Transformation of Clinical Trials with Predictivv
PRA Named Clinical Company of the Year
PRA Sponsors Russian Regional Quality Assurance Forum
PRA Health Sciences, Inc. Reports First Quarter 2015 Results
PRA is Named International Clinical Company of the Year
27 April 2015, Raleigh, N.C. - PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London. This is the second year in a row that PRA has won this prestigious award. PRA also swept the Clinical Team of the Year category. PRA winners include: • Clinical Research Associate: Charlotte Holmes • Project Manager: Silvia Casellas • Clinical Team Leader: Emma Lewis • Clinic ... Read More
PRA Health Sciences to Add New Jobs in Swansea
17 April 2015, Raleigh, N.C. - PRA Health Sciences (PRA), a leading global clinical research organization, is expanding its business in Swansea with the creation of 87 new jobs. The expansion will be supported by £990,060 of business finance from the Welsh Government enabling PRA to grow its local workforce to 280 by December 2017. This growth follows a recent expansion that saw over 100 new jobs created in PRA’s Swansea location, doubling the local workforce. The initial expansion wa ... Read More
PRA Health Sciences to Report First Quarter 2015 Results
17 April 2015, Raleigh, N.C. - PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2015 results after the market closes on Wednesday, May 6, 2015. The Company will also host a conference call and webcast on Thursday, May 7, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximate ... Read More
PRA Health Sciences Expands Global Phase I Patient Strategy
PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are being undertaken in response to market demand to include patients as early as possible in early phase clinical trial development and include:
• Opening an 11,000 square foot outpatient facility at PRA’s Salt Lake City, Utah site, focusing on psychiatry, neurology, pain and multiple oth ... Read More
PRA Health Sciences, Inc. Reports 4th Quarter and Full Year 2014 Results and 2015 Guidance
• $323.8 million of service revenue in the fourth quarter; 8% consolidated service revenue growth compared to the fourth quarter of 2013. • $50.6 million of Adjusted EBITDA in the fourth quarter; 44% growth compared to the fourth quarter of 2013. • Fourth quarter Adjusted Net Income per share increased 35% to $0.35 per share and Adjusted Net Income increased 80% to $18.6 million compared to the fourth quarter of 2013. • Fourth quarter GAAP Net Loss per share was $0.45 a ... Read More
PRA Health Sciences Announces Appointment of New Director
9 February, 2015, Raleigh, N.C. – PRA Health Sciences, Inc. (NASDAQ: PRAH) today announced the appointment of Matthew P. Young to the Board of Directors of the Company. As a member of the Board of Directors, Mr. Young will also serve on the Audit Committee.
“We are delighted that Matthew will be joining our Board of Directors. Not only does he bring significant expertise in all aspects of corporate finance, but much of his career has been spent in the healthcare and life sc ... Read More
PRA Health Sciences to Report Fourth Quarter 2014 Earnings
4 February, 2015, Raleigh, N.C. - PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18, 2015. The Company will also host a conference call and webcast on Thursday, February 19, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7 ... Read More
PRA Health Sciences, Inc. Announces Pricing of its Initial Public Offering
PRA Health Sciences Announces Pricing of its Initial Public Offering
12 November 2014, Raleigh, N.C. – PRA Health Sciences, Inc. (“PRA”), a leading global contract research organization, today announced the pricing of its initial public offering of 16,976,744 shares of its common stock at $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2014 under the ticker symbol “PRAH,” and the offering is expected to close on November 18, 2014, subject to customary closing conditions. PRA has gra ... Read More
PRA Health Sciences Files for Initial Public Offering
08 September 2014, Raleigh, N.C. PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (“IPO”) of shares of its common stock by PRA Health Sciences and an affiliate of Kohlberg Kravis Roberts & Co. L.P. (the “Selling Stockholder”). The number of shares to be offered and the price range has not yet been determined.
PRA Health S ... Read More
PRA Health Sciences Expands in Pennsylvania
PRA Health Sciences Expands
26 August 2014, Blue Bell, PA – Blue Bell, Pennsylvania will soon be home to PRA Health Sciences’ largest office worldwide. PRA, a leading global Contract Research Organization (CRO), is relocating employees from its Horsham and Fort Washington locations into new modern Class A+ office space in Blue Bell. The new office opened this week and marks the first phase of the relocation plan.
“This is an exciting time for us at PRA,” said Harris Koffer, President of the Stra ... Read More
PRA Advances to Become PRA Health Sciences
The Future of Clinical Development Today
16 June 2014, RALEIGH, NC – PRA, a leading clinical research organization, today announced that it has changed its name to PRA Health Sciences (PRA). The name change to PRA Health Sciences is the culmination of several strategic actions which support and enhance the company’s commitment to the future of clinical development.
Starting over 18 months ago, PRA strategically strengthened its coverage of China and created a joint venture with the leading clinical development fir ... Read More
PRA Completes 20th First in Human Biologics Trial
600 Subjects Enrolled Over an Eight-Year Period
27 May 2014, RALEIGH, N.C. – PRA, a leading clinical research organization, today announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience.
Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of ... Read More
PRA Adds Large Molecule Capabilities to U.S. Laboratory
Immunochemistry Services Now Available in Kansas
13 May 2014, RALEIGH, N.C. and LENEXA, Kansas – PRA, a leading clinical research organization, today announced that in addition to offering full-service bioanalytical capabilities in its Assen, The Netherlands, laboratory, it will add immunochemistry services in its Lenexa, Kan., laboratory. PRA is now the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in both the U.S. and Europe, facilita ... Read More
PRA Recognized for Quality with Multiple CRO Leadership Awards
Awards Honor Industry’s Top CROs
6 March, 2014, RALEIGH, N.C. – PRA, a leading clinical research organization, today announced it has won two CRO Leadership Awards for quality. For its full-service offering, PRA received the “Quality in Emerging Biotech” award, while its Embedded services division, RPS Strategic Solutions, received the “Overall Quality” award. Organized by Life Science Leader Magazine, the annual competition recognizes CROs for outstanding strides in key areas of trial delivery.
“ ... Read More
PRA Named “International Clinical Company of the Year” in Global Contest
Six PRA Employees Win Awards in Three Categories
11 February, 2014, RALEIGH, N.C. – PRA, a leading clinical research organization, today announced it has been named the 2014 “International Clinical Company of the Year” at the competition’s finals ceremony recently held in London. In addition, several PRA employees received individual honors.
Organized by PharmaTimes, the event named PRA “International Clinical Company of the Year” based on the total points earned by its employees’ performances in individual comp ... Read More
PRA Nominated for “Best CRO” Award in Global Contest for Second Year
Awards Honor Organizations in Asia’s Biopharmaceutical Industry
9 January, 2014, RALEIGH, N.C. – PRA, a leading clinical research organization, today announced it is a finalist in the category of Best Life Science Contract Research Organization of the Year for the 4th annual BioPharma Asia Industry Awards. Last year, PRA was voted “Best CRO” for the 3rd annual BioPharma Asia Industry Awards.
This year’s winner will be determined by an online voting contest. Voting is currently open and closes Feb. 28. To vote, go to http://svy.mk/1f ... Read More